Targeting the RET pathway in thyroid cancer.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• The RET protooncogene encodes a transmembrane receptor involved in cell signaling.
• RET mutations are linked to hereditary endocrine neoplasias and Hirschsprung's disease.
• Somatic RET mutations and rearrangements are implicated in sporadic thyroid cancers.

Purpose of the Study:

• To review the role of the RET protooncogene in cancer development and treatment.
• To highlight the significance of RET in multiple endocrine neoplasia syndromes and thyroid cancer.
• To discuss the therapeutic potential of targeting the RET pathway.

Main Methods:

• Literature review of studies on RET protooncogene function, mutations, and clinical implications.
• Analysis of RET's role in hereditary syndromes (MEN2A, MEN2B, FMTC) and sporadic cancers.
• Examination of therapeutic strategies targeting the RET pathway.

Main Results:

• Germline RET mutations cause MEN2A, MEN2B, FMTC, and Hirschsprung's disease.
• Somatic RET mutations occur in ~50% of sporadic medullary thyroid carcinoma (MTC).
• RET/PTC oncogenes, activated by chromosomal rearrangements, drive papillary thyroid carcinomas.
• Early thyroidectomy prevents MTC in individuals with inherited RET mutations.
• Targeted RET therapies show promise for advanced MTC.

Conclusions:

• The RET protooncogene is a critical target for cancer prevention and therapy.
• Genetic screening and prophylactic thyroidectomy are vital for hereditary RET-associated syndromes.
• Targeted molecular therapies represent a new frontier for treating RET-driven cancers, especially MTC.